Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com

Research analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research note issued to investors on Sunday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

NASDAQ EVOK opened at $5.07 on Friday. Evoke Pharma has a one year low of $3.54 and a one year high of $14.16. The firm has a market cap of $7.53 million, a P/E ratio of -0.46 and a beta of 0.16. The stock’s 50-day moving average is $4.95 and its 200-day moving average is $5.30.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent SEC filing.

Evoke Pharma Company Profile

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.